Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
08/28/2019
Trade Name:
Harvoni Oral Pellets
Generic Name or Proper Name (*):
ledipasvir and sofosbuvir
Indications Studied:
Treatment of chronic hepatitis C virus
Label Changes Summary:
*Expanded indication to pediatric patients 3 to 11 years; previously approved in pediatric patients 12 years and older. *Safety and efficacy have not been established in pediatric patients less than 3 years of age. *Adverse reactions were similar to those observed in adults. *Information on dosing, preparation and administration of oral pellets, PK parameters, adverse reactions, clinical trial. *New dosage form.
BPCA(B) and PREA(P):
B,P
Sponsor:
Gilead Sciences, Inc.
Pediatric Exclusivity Granted Date:
07/23/2019
NNPS:
FALSE
Therapeutic Category:
Antiviral
-
-